Our study revealed the cooperation between EZH2 and TGFβ signaling in promoting bone metastasis of breast cancer through a methyltransferase-independent mechanism, and demonstrated that targeting FAK may be an effective strategy for treatment of EZH2-induced breast cancer bone metastasis. Here, EZH2 is linked to breast cancer.